News from Monday, March 3, 2025
Articles
Value Viewpoint: February 28, 2025
(2/28, Kimberly Westrich, LinkedIn) comments “...Last week, a new article published in Clinical Pharmacology & Therapeutics, co-authored by ICER and the National Health Care Institute (Netherlands), explored an interesting question about the differing evidence needs for regulatory approval and health technology assessment. Although the article is labeled as a review, it’s an opinion-based commentary with selected case studies stitched together to tell a preconceived story. Everyone is entitled to their opinion, but let’s label them as such. If you are looking for a thoughtful review of the issue, this isn't it.” Full
From Research to Reality: How Studying Innovative HIV Medicines in the “Real World” Helps HCPs and Patients Make the Best Decisions for Treatment and Prevention
(3/3, Dr. Luis Buzón, Fierce Healthcare) comments “...Real-world evidence gives me confidence that I’m using the right therapeutic approach for each of my patients. Many of them are keen to learn more about their medicines and being able to tell them about the experiences of hundreds, or even thousands, of other people similar to them can help them understand their own therapies, and make them feel more comfortable with the approach we’re taking.” Full
Patients, Providers, and Researchers Agree: The Agency for Health Research and Quality is Critically Important
(3/3, Josh Caplan, M.A., M.P.P., Madison Haiman, M.S.W., AcademyHealth Blog) comments “...A large part of AHRQ’s research portfolio is focused on supporting the implementation of evidence-informed interventions to improve health...While there is still a risk of AHRQ being dismantled during the FY26 appropriations process, AcademyHealth is proud to be leading a strong advocacy campaign to preserve the Agency. We are asking for the Friends of AHRQ FY26 letter to be disseminated widely to congressional offices and staff.” Full
Press Releases
Rare Disease Day Shines a Light on Lennox-Gastaut Syndrome Research Powered by PCORnet
(2/28, PCORnet News Release) “...‘One of the major challenges in studying LGS is that there is no established computable phenotype,’ said [principal investigator Sandi Lam, MD, MBA]. ‘By leveraging the vast data resources available through the PCORnet infrastructure, we have an opportunity to develop a standardized way to identify LGS patients within electronic health records. This is critical because having a reliable method to identify and study LGS at scale can help researchers uncover new insights, improve diagnoses, and ultimately lead to better treatment options for these patients and their families.’” Full
Institute for Clinical and Economic Review Publishes Special Report on COPD Therapies as Part of CMS Public Comment Process on Medicare Drug Price Negotiations
(3/3, ICER Press Release) “The Institute for Clinical and Economic Review (ICER) today posted a Special Report evaluating the evidence of two Chronic Obstructive Pulmonary Disease (COPD) treatments, Trelegy Ellipta® and Breo Ellipta®, that will be sent as its public comment submission to Centers for Medicare & Medicaid Services (CMS) as part of its work on Medicare drug price negotiations. Both of the inhaler therapies were developed by GSK.” Full
Journals
Short- and Long-Term Comparative Effectiveness of Nirmatrelvir/Ritonavir and Molnupiravir in Asthma Patients: A Cohort Study
Guozhang Lin, et al.
February 28, 2025, Respiratory Research
Addressing Challenges with Matching-Adjusted Indirect Comparisons to Demonstrate the Comparative Effectiveness of Entrectinib in Metastatic ROS-1 Positive Non-Small Cell Lung Cancer
Cyril Esnault, et al.
March 1, 2025, BMC Medical Research Methodology
BMC Medical Research Methodology
Attitudes and Perceptions Regarding Knowledge Translation and Community Engagement in Medical Research: The PERSPECT Qualitative Study
Bogna A. Drozdowska, et al.
March 3, 2025, Health Research Policy and Systems
Reports
Special Assessment to Inform CMS Drug Price Negotiations: Trelegy Ellipta and Breo Ellipta for Patients with COPD
March 3, 2025